October 27, 2021 10:55 AM EDT

GSK brings Johns Hopkins prof and Blade co-founder on board; Evotec sets terms for $575M+ US IPO

John Carroll

Editor & Founder

Paul Schloesser

Associate Editor

Max Gelman

Senior Editor

GlaxoSmithKline CEO Emma Walmsley is adding another scientist to the company’s board. Early Wednesday — alongside their Q3 update — Walmsley put out …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK brings Johns Hopkins prof and Blade co-founder on board; Evotec sets terms for $575M+ US IPO

John Carroll

Editor & Founder

Paul Schloesser

Associate Editor

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

GSK brings Johns Hop­kins prof and Blade co-founder on board; Evotec sets terms for $575M+ US IPO

Editor & Founder

Associate Editor

Senior Editor

Sign up to read this article for free.

GSK brings Johns Hopkins prof and Blade co-founder on board; Evotec sets terms for $575M+ US IPO